Get the Stockscreener App
13.52
7.02%
-1.02
Pre-market:
14.33
0.81
+5.99%
Relay Therapeutics Inc stock is traded at $13.52, with a volume of 6.07M.
It is down -7.02% in the last 24 hours and up +4.00% over the past month.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.
See More
Previous Close:
$14.54
Open:
$14.54
24h Volume:
6.07M
Relative Volume:
1.65
Market Cap:
$2.95B
Revenue:
$15.36M
Net Income/Loss:
$-276.48M
P/E Ratio:
-8.3824
EPS:
-1.6129
Net Cash Flow:
$-235.87M
1W Performance:
-3.77%
1M Performance:
+4.00%
6M Performance:
+76.04%
1Y Performance:
+317.28%
1-Day Range:
$12.93
$14.54
1-Week Range:
$12.93
$17.47
52-Week Range:
$2.98
$17.47
Relay Therapeutics Inc Stock (RLAY) Company Profile
Name
Relay Therapeutics Inc
Sector
Industry
Phone
617-370-8837
Address
60 HAMPSHIRE STREET, CAMBRIDGE
Compare RLAY vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RLAY
Relay Therapeutics Inc
|
13.52 | 3.17B | 15.36M | -276.48M | -235.87M | -1.6129 |
VRTX
Vertex Pharmaceuticals Inc
|
446.83 | 112.12B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
635.45 | 65.92B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
891.32 | 52.38B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.05 | 40.54B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
149.23 | 33.10B | 742.00K | -1.37B | -1.07B | -7.0731 |
Relay Therapeutics Inc Stock (RLAY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-26-26 | Upgrade | Oppenheimer | Perform → Outperform |
| Dec-12-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Sep-04-25 | Resumed | Guggenheim | Buy |
| Apr-17-25 | Initiated | Wells Fargo | Equal Weight |
| Sep-10-24 | Resumed | Goldman | Buy |
| Sep-10-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-10-24 | Downgrade | Oppenheimer | Outperform → Perform |
| May-10-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Apr-20-23 | Upgrade | Jefferies | Underperform → Hold |
| Apr-19-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Apr-13-23 | Initiated | Raymond James | Outperform |
| Feb-03-23 | Initiated | Oppenheimer | Outperform |
| Sep-30-22 | Initiated | Barclays | Equal Weight |
| Sep-02-22 | Initiated | Stifel | Buy |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| Feb-01-22 | Initiated | Berenberg | Buy |
| Jul-21-21 | Initiated | BofA Securities | Buy |
| Dec-15-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-08-20 | Initiated | JMP Securities | Mkt Outperform |
| Nov-05-20 | Initiated | H.C. Wainwright | Buy |
| Aug-10-20 | Initiated | Cowen | Outperform |
| Aug-10-20 | Initiated | Goldman | Buy |
| Aug-10-20 | Initiated | Guggenheim | Buy |
| Aug-10-20 | Initiated | JP Morgan | Neutral |
View All
Relay Therapeutics Inc Stock (RLAY) Latest News
RLAY Technical Analysis | Trend, Signals & Chart Patterns | RELAY THERAPEUTICS INC (NASDAQ:RLAY) - ChartMill
RLAY stock lights up on vascular anomalies treatment data boost – 60% of patients show sharp reduction in lesion volume - MSN
RLAY Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Relay Therapeutics Hits Day High with 10.1% Surge in Strong Intraday Performance - Markets Mojo
Analysts Are Bullish on These Healthcare Stocks: Rezolute (RZLT), Relay Therapeutics (RLAY) - The Globe and Mail
Relay Therapeutics Hits New 52-Week High of $17.46, Up 108.5% - MarketsMojo
JonesTrading Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Relay Therapeutics stock hits 52-week high at 17.33 USD By Investing.com - Investing.com Canada
RLAY stock declines pre-market after $175M offering — despite fresh bullish calls on Relay's zovegalisib - MSN
Relay Therapeutics Shares Surge 20% on ASCO Momentum for Zovegalisib Breast Cancer Program - International Business Times Australia
Relay Therapeutics stock hits 52-week high at 17.33 USD - Investing.com
What Does Breakthrough Therapy Designation Mean for Relay Therapeutics - Kavout
Is Relay Therapeutics a Buy After Promising Trial Results? - AOL.com
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June - 富途牛牛
Sector Update: Healthcare - Moomoo
Relay Therapeutics Shares Reclaim Offer Price as Traders Eye June - Bez Kabli
Relay Therapeutics (RLAY) price target increased by 14.03% to 21.42 - MSN
Relay Therapeutics to present at two major healthcare investor conferences in June 2026 - Pluang
Relay Therapeutics leaders to join two June healthcare conferences - Stock Titan
Why Relay Therapeutics stock popped on Wednesday - MSN
RLAY Maintained by Guggenheim -- Price Target Raised to $26 - GuruFocus
RLAY Maintained by HC Wainwright & Co. -- Price Target Raised to $28 - GuruFocus
H.C. Wainwright raises Relay Therapeutics stock price target to $28 on trial data By Investing.com - Investing.com South Africa
Guggenheim raises Relay Therapeutics stock price target on drug profile By Investing.com - Investing.com Australia
H.C. Wainwright raises Relay Therapeutics stock price target to $28 on trial data - Investing.com Australia
Guggenheim raises Relay Therapeutics stock price target on drug profile - Investing.com
Guggenheim Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Raises Target Price to $26 - Moomoo
H.C. Wainwright Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Raises Target Price to $28 - Moomoo
Relay Therapeutics shares jump after positive vascular anomalies trial results (RLAY) - MSN
Relay rises on mid-stage trial data for lead asset in vascular anomalies - MSN
RLAY Stock Declines Pre-Market After $175M Offering — Despite Fresh Bullish Calls On Relay's Zovegalisib - Stocktwits
Relay Therapeutics, Inc. (RLAY) Presents at ISSVA World Congress 2026: The Latest in Vascular AnomaliesSlideshow (NASDAQ:RLAY) 2026-05-22 - Seeking Alpha
Relay Therapeutics prices $275M public offering of common stock at $12/share - MSN
Is Relay Therapeutics a Buy After Promising Trial Results? - The Motley Fool
Relay Therapeutics Inc Stock (RLAY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.13%
3.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):